Approximately 30% of advanced-stage prostate cancer patients’ exhibit cellular plasticity and acquisition of altered phenotypes often associated with the loss of AR signaling and/or alteration in AR splice variants [28,29]. The gene discussed is AR; the disease is prostate cancer.